In short
This article discusses the use of Nelivaptan (BH-200) in clinical trials for patients with Major Depressive Disorder (MDD). Nelivaptan is being studied in a Phase II clinical trial to assess its efficacy and tolerability in improving depressive symptoms. The trial is a 14-week, multicentre, double-blind, randomized, placebo-controlled study with an 8-week treatment period, focusing on outpatients with MDD.
At a glance
- Drug Name
- Nelivaptan (BH-200)
- Condition Studied
- Major Depressive Disorder (MDD)
- Trial Phase
- Phase II
- Trial Duration
- 14 weeks (8-week treatment period)
- Dosage
- 250 mg twice daily (500 mg total daily dose)
- Primary Objective
- Assess efficacy in improving depressive symptoms
- Key Inclusion Criteria
- Adults 18-75 years, MDD diagnosis, MADRS score ≥20
- Main Outcome Measures
- Change in HAMD-17 and MADRS scores, response and remission rates
- Safety Assessments
- Adverse events, laboratory tests, ECG, suicidality (C-SSRS)
What is Nelivaptan?
Nelivaptan, also known by its research code BH-200, is a new medication being studied for the treatment of Major Depressive Disorder (MDD). MDD is a serious mental health condition characterized by persistent feelings of sadness, loss of interest in activities, and other symptoms that significantly impact daily life. Nelivaptan is currently undergoing clinical trials to assess its effectiveness and safety in treating this condition.
How Nelivaptan Works
While the exact mechanism of action is not fully described in the available information, Nelivaptan appears to work differently from traditional antidepressants. It is being studied in patients with a specific genetic profile related to the V1b receptor, which is involved in the body's stress response system. This targeted approach suggests that Nelivaptan may be particularly effective for a subset of patients with depression who have this specific genetic makeup.
Current Research on Nelivaptan
Nelivaptan is currently being investigated in a Phase II clinical trial. This study is designed to evaluate the efficacy and tolerability of Nelivaptan in outpatients with Major Depressive Disorder. The trial has the following key features:
- It is a 14-week, multicentre study with an 8-week treatment period.
- The study is double-blind, randomized, and placebo-controlled, which means neither the patients nor the researchers know who is receiving the actual drug or a placebo during the trial.
- Participants receive a fixed dose of 250 mg of Nelivaptan twice daily (BID).
- The main goal is to assess how well Nelivaptan improves depressive symptoms compared to a placebo, especially in patients with a high V1b polygenic score.
Potential Benefits of Nelivaptan
The research on Nelivaptan aims to determine several potential benefits for patients with MDD:
- Improvement in depressive symptoms, as measured by standardized depression rating scales.
- Possible reduction in anxiety symptoms, which often co-occur with depression.
- Potential improvements in quality of life and overall functioning.
- A new treatment option for patients who may not have responded well to other antidepressants.
Who Can Take Nelivaptan?
As Nelivaptan is still in clinical trials, it is not yet available for general use. The current study has specific criteria for participation, including:
- Adults aged 18-75 (18-65 in Serbia) with a primary diagnosis of moderate to severe Major Depressive Disorder.
- Patients must have had symptoms of depression for at least 2 weeks prior to screening.
- Participants must be willing to stop current antidepressive medications before starting the trial.
There are also several exclusion criteria, such as certain medical conditions, substance use disorders, and high suicide risk.
Possible Side Effects and Safety Considerations
As Nelivaptan is still being studied, the full range of potential side effects is not yet known. The clinical trial is designed to assess the safety and tolerability of the medication. Some general safety considerations include:
- Patients with certain cardiovascular conditions, liver or kidney problems, or uncontrolled diabetes are excluded from the trial for safety reasons.
- The study will monitor for any adverse events and changes in vital signs, laboratory tests, and electrocardiogram (ECG) readings.
- Suicidality will be closely monitored throughout the trial.
Future Prospects for Nelivaptan
If the current Phase II trial shows promising results, Nelivaptan may proceed to larger Phase III trials. These would further evaluate its effectiveness and safety in a broader population of patients with MDD. If successful, Nelivaptan could potentially become a new treatment option for depression, particularly for patients with a specific genetic profile.
It's important to note that drug development is a long and complex process, and many promising medications do not make it to market. However, the research on Nelivaptan represents an exciting step forward in the search for new and more effective treatments for Major Depressive Disorder.